NMN (Nicotinamide Mononucleotide)

Evidence Level
Moderate
2 Clinical Trials
4 Documented Benefits
3/5 Evidence Score

NMN is a direct precursor to NAD+, a coenzyme essential for cellular energy production, DNA repair, and sirtuin activation. NAD+ levels naturally decline with age, and NMN supplementation is one of the most actively researched strategies for restoring NAD+ to support longevity and metabolic health.

Studied Dose 250–500 mg/day (commonly studied); up to 1,200 mg/day in clinical trials
Active Compound Beta-Nicotinamide Mononucleotide (NMN) — stabilized crystalline form

NAD+ restoration

NMN is rapidly converted to NAD+ in cells, restoring levels that decline 40–50% between ages 40 and 60. Higher NAD+ supports mitochondrial efficiency, DNA repair, and metabolic signaling.

Metabolic health

Human trials show NMN supplementation improves insulin sensitivity, reduces liver fat, and improves skeletal muscle insulin signaling — effects mediated through NAD+-dependent SIRT1 activation.

Muscle function and endurance

RCT in older adults showed NMN improved muscle strength, walking speed, and grip strength over 12 weeks, with effects correlating with blood NAD+ increases.

Cognitive support

Preclinical studies show NAD+ restoration improves neuronal function, reduces neuroinflammation, and supports DNA repair in brain cells. Human cognitive trial data is emerging.

1

NAD+ biosynthesis via salvage pathway

NMN is phosphorylated by NMN adenylyltransferases (NMNATs) to directly produce NAD+. This bypasses rate-limiting steps in other NAD+ precursor pathways, making NMN one of the most efficient NAD+ boosters.

2

Sirtuin activation

Elevated NAD+ activates sirtuins (SIRT1–7), a family of NAD+-dependent deacetylases that regulate gene expression, mitochondrial biogenesis, inflammation, and stress resistance — key longevity pathways.

3

PARP-1 support for DNA repair

NAD+ is consumed by PARP-1 during DNA repair. Restoring NAD+ ensures adequate substrate for DNA damage repair, reducing genomic instability associated with aging.

1
NMN Supplementation and Muscle Function in Older Adults
PubMed

RCT of 250 mg/day NMN vs. placebo in 42 older adults (65+) for 12 weeks.

42 adults aged 65+. 12-week intervention.

NMN significantly increased blood NAD+ metabolites. Improved grip strength, walking speed, and timed chair-stand test vs. placebo. Well-tolerated with no serious adverse events.

2
Safety and Metabolism of NMN in Healthy Adults
PubMed

First human clinical trial of oral NMN: single doses of 100, 250, and 500 mg in 10 healthy men.

10 healthy men. Single-dose pharmacokinetic study.

All doses safely increased blood NAD+ metabolites within 2–3 hours. No adverse effects on vital signs, metabolic markers, or hormones at any dose. Established safety profile for human use.

Common Potential side effects

Generally well-tolerated in clinical studies up to 1,200 mg/day
Mild nausea or GI discomfort reported by some users at higher doses
Long-term safety data in humans still accumulating — most trials are 12 weeks or less

Important Drug interactions

No established drug interactions — emerging safety data
Theoretically, may interact with medications metabolized through SIRT1/NAD+ pathways
Consult physician if taking immunosuppressants or chemotherapy agents